Since July, major multinational pharmaceutical companies have entered the disclosure period of their semi-annual reports
.
At present, the time has come to August, and the semi-annual reports of major multinational pharmaceutical companies have been released one after another
.
Below, the author will take you to take a detailed look at the performance of some companies
.
Pfizer
Pfizer
On July 28, Pfizer announced its second quarter and half-year results for 2022
.
Data shows that the company’s Q2 revenue was US$27.
742 billion, a year-on-year increase of 47%; net profit was US$9.
906 billion, a year-on-year increase of 78%
.
In the first half of the year, Pfizer's total revenue was US$53.
402 billion, a year-on-year increase of 60%; net profit was US$17.
769 billion, a year-on-year increase of 70%
.
R&D investment was US$5.
116 billion, a year-on-year increase of 21%
.
It is understood that Pfizer achieved a new record in performance, mainly due to the strong demand for new crown vaccines and new crown oral drugs
.
Notably, this achievement also gives Pfizer the confidence to find new assets to expand its pipeline
.
Recently, it was reported that Pfizer is considering the acquisition of Global Blood Therapeutics (GBT) for $5 billion
.
MSD
MSD
On July 28, Merck released its second quarter and semi-annual performance report for 2022
.
According to the data, the company’s Q2 revenue was US$14.
593 billion, a year-on-year increase of 28% (excluding the sales of the new crown oral drug LAGEVRIO, which increased by 18% year-on-year); the revenue in the first half of 2022 was US$30.
494 billion, an increase of 38% year-on-year, and the net profit in the first half of the year was 8.
254 billion U.
S.
dollar, up 75% from the same period last year
.
According to the announcement, the improvement in its performance was mainly due to the recovery of the epidemic and the performance of the new coronavirus drug Molnupiravir
.
Looking ahead to the full-year performance, Merck raised its expected sales in 2022 to $57.
5 billion to $58.
5 billion, a full-year increase of 18%-20%
.
Among them, Monelavir's expected annual sales will reach 5 billion -5.
5 billion US dollars
.
AbbVie
AbbVie
On July 29, AbbVie announced its 2022H1 performance report
.
Data shows that the company's Q2 operating income was US$14.
583 billion, up 4.
47% year-on-year; net profit was US$924 million, up 20.
63% year-on-year
.
In the first half of 2022, AbbVie's total revenue was $28.
121 billion, a year-on-year increase of 4.
3%; and $5.
414 billion, a year-on-year increase of 25.
35%
.
R&D investment was US$3.
106 billion, a year-on-year decrease of 9.
55%
.
Judging from the announcement, the self-free business income has supported half of AbbVie’s country.
Specifically, Humira (adalimumab) revenue rose slightly by 1.
7% to US$10.
099 billion, and it is still expected to continue to exceed US$20 billion this year
.
AstraZeneca
AstraZeneca
On July 29, AstraZeneca announced its financial results for the first half of 2022
.
According to the financial report, the company’s Q2 revenue was US$10.
771 billion, a year-on-year increase of 37%; the revenue in the first half of the year was US$22.
161 billion, a year-on-year increase of 48%; R&D investment was US$4.
679 billion, a year-on-year increase of 35%, accounting for 21% of revenue
.
In addition to the above pharmaceutical companies, Johnson & Johnson, Novartis, Biogen, Roche, Sanofi, GSK and other companies have also released semi-annual reports
.
On the whole, blockbuster drugs are still growing strongly.
Vaccines and drugs directly related to the epidemic have also become new strong growth points that drive corporate performance after they continue to enter the commercialization stage
.
Among them, Pfizer has been firmly in the forefront with its superior performance of new crown vaccines and new crown drugs.
The first half revenue of the new crown vaccine Comirnaty product alone has exceeded the total revenue of an MNC in the first half of the year
.
The industry expects that with the collection of payments in the second half of the year, Comirnaty's sales will increase cumulatively
.
However, in contrast, most other multinational pharmaceutical companies have also seen growth in performance, but at the same time there has been a slowdown in performance
.
